|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 1393477-72-9 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
Fields of Application :
KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor.
| CAS Number: | 1393477-72-9 |
| Purity: | >98% |
| Molecular Weight: | 443.31 |
| Molecular Formula: | C17H11F6N7O |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | KPT330; KPT 330 |
| Chemical Name: | (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
As the clinical candidate analog of KPT-185, KPT-330 exhibits similar effects on the viability of T-ALL cells and elicits rapid apoptotic response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines, with IC50 values of 34-203 nM. KPT-330 dramatically suppresses the growth of T-ALL cells (MOLT-4) and AML cells (MV4–11) in vivo, with little toxicity to normal haematopoietic cells. In SCID mice with diffuse human MM bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs. For the detailed information of KPT-330, the solubility of KPT-330 in water, the solubility of KPT-330 in DMSO, the solubility of KPT-330 in PBS buffer, the animal experiment (test) of KPT-330, the cell expriment (test) of KPT-330, the in vivo, in vitro and clinical trial test of KPT-330, the EC50, IC50,and Affinity of KPT-330.
References:
C1=CN=C(C=N1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
